Cancer drug interaction study: will antibiotics change how cediranib works?
NCT ID NCT00750841
First seen Jun 25, 2026 · Last updated Aug 18, 2026 · Updated 3 times
Summary
This Phase 1 study looks at how the antibiotic rifampicin changes the way the body processes the experimental cancer drug cediranib in 64 patients with advanced solid tumors. Participants take cediranib alone, then with rifampicin, then alone again to compare drug levels and safety. The goal is to understand drug interactions, not to test if cediranib shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- cediranib (experimental cancer drug) and rifampicin (antibiotic)
- What this could lead to
- If successful, this study could help doctors understand how to safely combine cediranib with other drugs that affect liver enzymes, potentially improving future dosing guidelines.
- What could go wrong
- This is an early, small Phase 1 study focused on drug interaction, not treatment effectiveness. It may not lead to any direct benefit for participants, and side effects from the drug combination are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
64 people
The number who actually took part.
- Started
-
Sep 2008
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 130 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Written informed consent * Prostate cancer), which is refractory to standard therapies or for which no standard therapy exists. * Estimated life expectancy of at least 8 weeks * WHO performance status (PS) 0-2. Exclusion Criteria: * Unstable brain/meningeal metastases * Biochemistry/haematology results outside of required ranges * History of significant GI impairment * Inadequate bone marrow reserve
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Advanced solid tumor are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Edmonton, Alberta, T6G 1Z2, Canada
-
Research Site
Montreal, Quebec, H3T 1E2, Canada
-
Research Site
Dundee, DD1 9SY, United Kingdom
-
Research Site
Glasgow, G12 0YN, United Kingdom
-
Research Site
London, NW1 2PG, United Kingdom
-
Research Site
London, SE1 9RT, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Oral drug that targets two cancer drivers tested in first human study
- Mitochondria-Targeting drug gamitrinib tested for first time in humans
- Can a Two-Drug combo outsmart advanced cancer?
- Can an experimental pill boost cancer immunotherapy? early trial puts HG146 to the test
- New injectable drug tested for safety in Hard-to-Treat solid tumors
- New antibody drug conjugate tested against advanced cancers